Eli Lilly surges past estimates, boosts guidance as drug sales skyrocket
Eli Lilly's strong second-quarter performance has exceeded expectations, driven by booming sales of its diabetes medication Mounjaro and weight loss injection Zepbound. The company has significantly raised its revenue outlook…